CardiOx seeks $4 million to support launch of heart defect test

01/4/2013 |

CardiOx is looking to raise $4 million in a funding round as the company awaits regulatory clearance for its flagship product: a noninvasive test to detect a heart defect called patent foramen ovale. The Columbus, Ohio-based company will use the money to launch the assay during the first half of the year, said CEO Larry Heaton.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
Springfield, OR
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA